The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump’s planned pharmaceutical tariffs.
Related Posts
Britain takes stake in SpaceX rival Orbex to boost space ambitions
The U.K. government has invested £20 million in Orbex, a Scottish spaceflight startup aiming to rival Elon Musk’s SpaceX.
Musk’s xAI releases artificial intelligence model Grok 3, claims better performance than rivals in early testing
Elon Musk’s artificial intelligence company xAI has unveiled its latest AI chatbot, Grok 3, as its competition with OpenAI and DeepSeek heats up.
Two retailers could end up beneficiaries of tariffs, says Citi in upgrade
Citi analyst Paul Lejeuz upgraded shares of both TJX Companies and Ross Stores to a buy rating from neutral.